Annette North joined Turning Point Therapeutics in April 2019 as executive vice president and general counsel. Ms. North also serves as company secretary. She brings more than 25 years of experience serving biotechnology companies from inception through private and public fundraising, business development, and mergers and acquisitions. Ms. North previously served as a senior executive and general counsel for Kura Oncology and Wellspring Biosciences. At Kura, she was responsible for all legal affairs, including corporate governance and compliance, intellectual property, the company’s financings and public listing on the NASDAQ stock market, and initiation of a pivotal global clinical trial. Prior to Kura, Ms. North served as senior vice president and general counsel at Ambit Biosciences from initial public offering and initiation of a pivotal global clinical trial through acquisition by Daiichi Sankyo. Prior to Ambit, she held legal roles at SGX Pharmaceuticals, Axys Pharmaceuticals, Sequana Therapeutics, and private law firms. Ms. North earned her Bachelor of Laws and Bachelor of Commerce degrees from Melbourne University in Australia, and is a member of the State Bar of California.